Study of the combined and separate administration of doxorubicin and coenzyme Q10 on mouse cardiac enzymes.
Administration of an acutely toxic dose of doxorubicin to mice did not increase, but rather decreased the percent deficiency of coenzyme Q10 (CoQ10) as calculated according to the coenzyme-apoenzyme system principle. The date indicate that doxorubicin may occupy CoQ10-empty receptors on the apoenzyme, with or without some destruction of enzyme-menbrane structure close to the receptor. Data from mice receiving both CoQ10 and doxorubicin indicated that CoQ10 may protect against doxorubicin. CoQ10 alone corrected the pre-existing deficiency found in control mice.
D000818:Animals; D004317:Doxorubicin / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008929:Mitochondria, Heart / Q000187:drug effects / Q000201:enzymology; D009206:Myocardium / Q000201:enzymology*; D013385:Succinate Dehydrogenase / Q000172:deficiency / Q000378:metabolism*; D014451:Ubiquinone / Q000378:metabolism / Q000494:pharmacology*
D014451:Ubiquinone; D004317:Doxorubicin; D013385:Succinate Dehydrogenase